Movement Alert｜Caris Life Sciences, Inc. Intraday Rise 5.99% in Regular Trading, BofA Securities Raised Price Target to $35

Market Focus10-14

On October 14, Caris Life Sciences, Inc. recorded an Intraday Rise of 5.99% in Regular Trading, with the stock trading at $31.2853 and turnover of $13.796 million.

The clearest recent catalyst is BofA Securities raising its price target on Caris Life Sciences, Inc. to $35 from $23 on October 9, a level above the $27.08 analyst mean target cited at the time, which provided support for sentiment toward the shares.

The target-price revision followed improving operating results earlier in the year. Caris Life Sciences, Inc. reported second-quarter revenue of $263.712 million, above the $238.125 million consensus estimate. In the first quarter, revenue rose to $216.2 million from $120.9 million a year earlier, earnings reached breakeven versus expectations for a small loss, and the company reaffirmed full-year revenue guidance of $1.0 billion to $1.02 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment